C4 Therapeutics, Inc.

NasdaqGS:CCCC Stock Report

Market Cap: US$144.1m

C4 Therapeutics Management

Management criteria checks 1/4

C4 Therapeutics' CEO is Andrew Hirsch, appointed in Sep 2020, has a tenure of 4.5 years. total yearly compensation is $3.79M, comprised of 16.9% salary and 83.1% bonuses, including company stock and options. directly owns 0.11% of the company’s shares, worth $165.03K. The average tenure of the management team and the board of directors is 1.7 years and 7.7 years respectively.

Key information

Andrew Hirsch

Chief executive officer

US$3.8m

Total compensation

CEO salary percentage16.9%
CEO tenure4.5yrs
CEO ownership0.1%
Management average tenure1.7yrs
Board average tenure7.7yrs

Recent management updates

Recent updates

C4 Therapeutics: Getting Too Cheap To Ignore, But There's Still A Lot Of Risk Here

Mar 10

C4 Therapeutics, Inc. (NASDAQ:CCCC) Looks Inexpensive After Falling 31% But Perhaps Not Attractive Enough

Mar 04
C4 Therapeutics, Inc. (NASDAQ:CCCC) Looks Inexpensive After Falling 31% But Perhaps Not Attractive Enough

C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 33% Share Price Plunge Could Signal Some Risk

Nov 15
C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 33% Share Price Plunge Could Signal Some Risk

C4 Therapeutics: Holding Fast To A Generous Valuation Heading Into An Important ASH Readout

Nov 06

We're Not Very Worried About C4 Therapeutics' (NASDAQ:CCCC) Cash Burn Rate

Oct 02
We're Not Very Worried About C4 Therapeutics' (NASDAQ:CCCC) Cash Burn Rate

Analysts' Revenue Estimates For C4 Therapeutics, Inc. (NASDAQ:CCCC) Are Surging Higher

Aug 09
Analysts' Revenue Estimates For C4 Therapeutics, Inc. (NASDAQ:CCCC) Are Surging Higher

C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 41% Share Price Surge Not Quite Adding Up

Aug 03
C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 41% Share Price Surge Not Quite Adding Up

Analysts Just Published A Bright New Outlook For C4 Therapeutics, Inc.'s (NASDAQ:CCCC)

May 12
Analysts Just Published A Bright New Outlook For C4 Therapeutics, Inc.'s (NASDAQ:CCCC)

C4 Therapeutics' TORPEDO Platform Is Promising, But Its Valuation Remains Stretched

Mar 01

Party Time: Brokers Just Made Major Increases To Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Earnings Forecasts

Feb 29
Party Time: Brokers Just Made Major Increases To Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Earnings Forecasts

C4 Therapeutics, Inc. (NASDAQ:CCCC) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Feb 24
C4 Therapeutics, Inc. (NASDAQ:CCCC) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

New Forecasts: Here's What Analysts Think The Future Holds For C4 Therapeutics, Inc. (NASDAQ:CCCC)

Nov 03
New Forecasts: Here's What Analysts Think The Future Holds For C4 Therapeutics, Inc. (NASDAQ:CCCC)

Analysts Are Betting On C4 Therapeutics, Inc. (NASDAQ:CCCC) With A Big Upgrade This Week

May 14
Analysts Are Betting On C4 Therapeutics, Inc. (NASDAQ:CCCC) With A Big Upgrade This Week

C4 Therapeutics wins FDA nod to study cancer candidate in solid tumors

Sep 29

C4 Therapeutics GAAP EPS of -$0.56 beats by $0.12, revenue of $13.84M beats by $5.33M

Aug 04

Earnings Release: Here's Why Analysts Cut Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Price Target To US$29.00

May 10
Earnings Release: Here's Why Analysts Cut Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Price Target To US$29.00

C4 Therapeutics: Poor Data Destroyed Preclinical Promise

May 04

CEO Compensation Analysis

How has Andrew Hirsch's remuneration changed compared to C4 Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024n/an/a

-US$105m

Sep 30 2024n/an/a

-US$105m

Jun 30 2024n/an/a

-US$108m

Mar 31 2024n/an/a

-US$126m

Dec 31 2023US$4mUS$639k

-US$132m

Sep 30 2023n/an/a

-US$135m

Jun 30 2023n/an/a

-US$140m

Mar 31 2023n/an/a

-US$131m

Dec 31 2022US$3mUS$614k

-US$128m

Sep 30 2022n/an/a

-US$107m

Jun 30 2022n/an/a

-US$99m

Mar 31 2022n/an/a

-US$95m

Dec 31 2021US$952kUS$580k

-US$84m

Sep 30 2021n/an/a

-US$80m

Jun 30 2021n/an/a

-US$82m

Mar 31 2021n/an/a

-US$73m

Dec 31 2020US$21mUS$168k

-US$66m

Compensation vs Market: Andrew's total compensation ($USD3.79M) is above average for companies of similar size in the US market ($USD644.77K).

Compensation vs Earnings: Andrew's compensation has increased whilst the company is unprofitable.

CEO

Andrew Hirsch (53 yo)

4.5yrs

Tenure

US$3,790,099

Compensation

Mr. Andrew J. Hirsch, M.B.A., is the President of C4 Therapeutics, Inc since September 14, 2020 and has been its Chief Executive Officer since October 2, 2020. Mr. Hirsch has been Director of C4 Therapeuti...

Leadership Team

NamePositionTenureCompensationOwnership
Andrew Hirsch
CEO, President & Director4.5yrsUS$3.79m0.11%
$ 165.0k
Kenneth Anderson
Co-Founderno dataUS$111.41k0.46%
$ 656.7k
Stewart Fisher
Consultantless than a yearUS$1.53m0.12%
$ 170.3k
Leonard M. Reyno
Chief Medical Officer1.7yrsUS$1.96m0.019%
$ 26.7k
Nathanael Gray
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Kendra Adams
CFO & Treasurer1.5yrsno data0.034%
$ 49.2k
Mark Mossler
Chief Accounting Officer1.5yrsno data0.0063%
$ 9.1k
Paige Mahaney
Chief Scientific Officerless than a yearno datano data
Courtney Solberg
Senior Manager of Investor Relationsno datano datano data
Jolie Siegel
Chief Legal Officer & Corporate Secretary4.7yrsUS$3.38m0.030%
$ 42.6k
Kelly Schick
Chief People Officer4.2yrsno data0.031%
$ 44.5k
Isabel Chiu
Senior Vice President of Strategic Alliances & Business Development9yrsno datano data

1.7yrs

Average Tenure

53yo

Average Age

Experienced Management: CCCC's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Andrew Hirsch
CEO, President & Director4.4yrsUS$3.79m0.11%
$ 165.0k
Kenneth Anderson
Co-Founder9.3yrsUS$111.41k0.46%
$ 656.7k
Nathanael Gray
Co-Founder & Member of Scientific Advisory Board8.3yrsno datano data
Bruce Downey
Lead Independent Director9.3yrsUS$157.91k0.69%
$ 993.8k
Christopher Bowden
Member of Clinical Advisory Boardno datano datano data
Christopher Kirk
Member of Scientific Advisory Board8.3yrsno datano data
Ross Levine
Member of Scientific Advisory Board7.7yrsno datano data
Ronald H. Cooper
Independent Chairmanless than a yearno datano data
Ryan Corcoran
Member of Scientific Advisory Board5.5yrsno datano data
Scott Armstrong
Member of Scientific Advisory Board7.7yrsno datano data
Utpal Koppikar
Independent Director3yrsUS$126.41k0.0080%
$ 11.5k
Beni Wolf
Member of Clinical Advisory Boardno datano datano data

7.7yrs

Average Tenure

57yo

Average Age

Experienced Board: CCCC's board of directors are considered experienced (7.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/16 16:57
End of Day Share Price 2025/03/14 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

C4 Therapeutics, Inc. is covered by 16 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Clarence PowellBMO Capital Markets Equity Research
Etzer DaroutBMO Capital Markets Equity Research
George FarmerBMO Capital Markets Equity Research